Skip to content

Clinical Evaluation of A New High-speed and High-resolution Intravascular Ultrasound System

Clinical Evaluation of A New High-speed and High-resolution Intravascular Ultrasound System: A Multi-center Prospective Control Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04739657
Acronym
NEW-IVUS
Enrollment
130
Registered
2021-02-04
Start date
2021-03-01
Completion date
2021-04-27
Last updated
2022-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Total Occlusion of Coronary Artery, Coronary Artery Disease, Left Main Coronary Artery Disease, Percutaneous Coronary Intervention

Keywords

high-speed, high-resolution IVUS

Brief summary

Insight Lifetech Intravascular Ultrasound Diagnostic System (referred to as Insight Lifetech IVUS system below),is a new high-speed and high-resolution device for clearly defining vessel architecture and plaque morphology, providing quantitative and qualitative assessment of coronary arteries. Besides, IVUS has already an established role in guidance and optimization of percutaneous coronary intervention. This study will compare the differences, if any, between the intravascular ultrasound(IVUS) results measured by the two different IVUS diagnostic systems.

Detailed description

Many studies have reported that IVUS is an accurate method for determining the size of the target vessel undergoing stent implantation , and the optimal stent deployment (complete stent expansion and apposition and lack of edge dissection or other complications after implantation). The novel 60 megahertz(60MHz) high-definition IVUS has evolved as a next-generation IVUS imaging technology to provide higher image resolution than conventional 40 megahertz(40MHz) IVUS but with sufficient imaging depth preserved for the assessment of the entire vessel wall structure. Insight Lifetech IVUS system includes TrueVision IVUS diagnostic catheter and VivoHeart IVUS diagnostic console. It is a novel device with high speed, high resolution, and high image acquisition rate enabling high-speed pullback imaging up to 10mm/sec. This study is a prospective, multi-center, randomized, single-blind, controlled study with the primary target of investigating the differences, if any, between IVUS measurement results by the Insight Lifetech IVUS system and Boston Scientific IVUS system, imaging catheter of which was available at 40MHz during the study. Other purposes included analyzing the feasibility of the Insight Lifetech IVUS system's high-speed pullback during the IVUS assessment. A total of 130 patients will be recruited from 5 centers in China.

Interventions

DEVICEInsight Lifetech IVUS System

The Insight Lifetech IVUS System is intended for examination of coronary intravascular pathology only, including TrueVision IVUS diagnostic catheter and VivoHeart IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.

DEVICEBoston Scientific IVUS System

The Boston Scientific IVUS System is intended for the examination of coronary intravascular pathology only, including Opticross IVUS diagnostic catheter and iLAB IVUS diagnostic device. IVUS imaging is used in patients who will undergo percutaneous coronary intervention.

Sponsors

Shanghai Zhongshan Hospital
CollaboratorOTHER
Guangdong Provincial People's Hospital
CollaboratorOTHER
Chinese PLA General Hospital
CollaboratorOTHER
Zhongda Hospital
CollaboratorOTHER
The First Affiliated Hospital of Zhengzhou University
CollaboratorOTHER
Insight Lifetech Co., Ltd.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age: 18 Years and older; * Understand and willing to sign the informed consent form; * Clinical evaluation shows that the coronary artery stent implantation and the intravascular ultrasound(IVUS) guidance is required.

Exclusion criteria

* Unable to understand or unwilling to sign the informed consent form; * Clinically diagnosed with severe coronary artery spasms; * Contraindicated to percutaneous coronary intervention (PCI); * Presence of any other factor that the investigator deems is unsuitable for enrollment or completion of this study.

Design outcomes

Primary

MeasureTime frameDescription
Mean Stent Area in square millimeter(MSA)estimated 1 month on average, by a third-party corelab IVUS image post-analysisComparison between the MSA measured by the Insight Lifetech Intravascular Ultrasound Diagnositic System and Boston Scientific Intravascular Ultrasound Diagnostic System, including mean relative deviation, confidence interval and standard deviation, as assessed by Bland-Altman analysis and Pearson correlation analysis.

Secondary

MeasureTime frameDescription
Minimal Lumen Area in square millimeter(MLA)estimated 1 month on average, by a third-party corelab IVUS image post-analysisComparison between the MLA measured by the Insight Lifetech Intravascular Ultrasound Diagnostic System and Boston Scientific Intravascular Ultrasound Diagnostic System, including mean relative deviation, confidence interval and standard deviation, as assessed by Bland-Altman analysis and Pearson analysis.
The rate of detected stent malapposition, tissue prolapse and dissectionestimated 1 month on average, by a third-party corelab IVUS image post-analysisDetection rate of poor adherence, tissue prolapse and intercalation, for each system individually, and comparison between the two systems.
Stability of system (questionnaire)estimated 1week on average, by opeartor's rating on questionaireEvaluate the stability of both systems concluded from all enrolled case using questionnaire, including below measures : 1. the stability of IVUS examination ; 2. the usability of system operation; 3. the definition of images. For each system in 1., 2., and 3., only one of the following five ratings is given: * very stable/convenient/clear images; * stable/convenient/clear images, inspection was unaffected; * slightly unstable/inconvenient/unclear images, inspection was unaffected; * unstable/inconvenient/unclear images, inspection was affected; (in the order of 1./2./3.) * N/A. and is counted as 1 point for that particular rating. The distribution of the points in rating and how many points each rating individually owns are compared between the systems.
Maneuvering performance of catheter (questionnaire)estimated 1week on average, by opeartor's rating on questionaireEvaluate the maneuvering performance of catheters in the two systems concluded from all enrolled case, including below measures : 1. the pushability 2. the crossability 3. the angiographic visibility For each system in 1., 2., and 3., only one of the following five ratings is given: * excellent pushability/lesion crossability/visibility; * pushing met slight resistance/crossed lesion smoothly/good visibility, inspection was unaffected; * pushing met obvious resistance/crossed lesion after attempts/mediocre visibility, inspection was unaffected; * too resistant to push/unable to cross lesion/very poor visibility, inspection was affected; (in the order of 1./2./3.) * N/A. and is counted as 1 point for that particular rating. The distribution of the points in rating and how many points each rating individually owns are compared between the systems.
Clear Stent Length in millimeter (CSL)estimated 1 month on average, by a third-party corelab IVUS image post-analysisComparison between the CSL measured by the Insight Lifetech Intravascular Ultrasound Diagnostic System and Boston Scientific Intravascular Ultrasound Diagnostic System, including mean relative deviation, confidence interval and standard deviation, as assessed by Bland-Altman analysis and Pearson analysis.
Rate of device-related adverse effectsestimated 1day on average, by intraoperative monitoringRate of device-related adverse effects, for each system individually, and comparison between the two systems.
Rate of thrombosis, diffuse lesion and re-stenosis as discerned by IVUSestimated 1 month on average, by a third-party corelab IVUS image post-analysisRate of thrombosis, diffuse lesion and re-stenosis discerned by each system individually, and comparison between the two systems.
Rate of plaque rupture and plaque properties as discerned by IVUSestimated 1 month on average, by a third-party corelab IVUS image post-analysisRates of plaque rupture, lipid-rich plaque, fibrous plaque and calcified plaque, discerned by each system individually, and comparison between the two systems.
Device success rateestimated 1day on average, by intraoperative monitoringDevice success rate, defined as a valid IVUS image for each system, and comparison between the two systems.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026